Traumatic brain injury (TBI) is a significant cause of disability and death and a huge economic burden throughout the world. Much of the morbidity associated with TBI is attributed to secondary brain injuries resulting in hypoxia and ischemia after the initial trauma. Intracranial hypertension and decreased partial brain oxygen tension (P bt O 2 ) are targeted as potentially avoidable causes of morbidity. Therapeutic hypothermia (TH) may be an effective intervention to reduce intracranial pressure (ICP), but could also affect cerebral blood flow (CBF). This is a retrospective analysis of prospectively collected data from 17 patients admitted to the Western General Hospital, Edinburgh. Patients with an ICP >20 mmHg refractory to initial therapy were randomized to standard care or standard care and TH (intervention group) titrated between 32°C and 35°C to reduce ICP. ICP and P bt O 2 were measured using the Licox system and core temperature was recorded through rectal thermometer. Data were analyzed at the hour before cooling, the first hour at target temperature, 2 consecutive hours at target temperature, and after 6 hours of hypothermia. There was a mean decrease in ICP of 4.3 -1.6 mmHg ( p < 0.04) from 15.7 to 11.4 mmHg, from precooling to the first epoch of hypothermia in the intervention group (n = 9) that was not seen in the control group (n = 8). A decrease in ICP was maintained throughout all time periods. There was a mean decrease in P bt O 2 of 7.8 -3.1 mmHg ( p < 0.05) from 30.2 to 22.4 mmHg, from precooling to stable hypothermia, which was not seen in the control group. This research supports others in demonstrating a decrease in ICP with temperature, which could facilitate a reduction in the use of hyperosmolar agents or other stage II interventions. The decrease in P bt O 2 is not below the suggested treatment threshold of 20 mmHg, but might indicate a decrease in CBF.
Introduction
T raumatic brain injury (TBI) is a significant cause of disability and death and a huge economic burden on our society. The incidence of TBI is rising throughout the world and the World Health Organization estimates that TBI will become a primary cause of death by the year 2020 (Hyder et al., 2007) . In the US, *1.7 million people suffer a TBI each year. Approximately 52,000 of these die and of those that survive to discharge, 43% have an ongoing disability 1 year after injury (Langlois et al., 2006; Corrigan et al., 2010) . The financial cost of TBI in the US in the year 2000 was estimated to be $406 billion (Corso et al., 2006) . In Europe there is an annual incidence of about 235 per 100,000 people and there are *7.7 million people suffering with disabilities due to TBI (Tagliaferri et al., 2006) .
Much of the morbidity of TBI is attributed to secondary injuries, which occur after the initial injury and are associated with a failure to maintain adequate oxygen delivery to the injured brain (Chesnut et al., 1993; Chesnut, 1995) . As part of the management of secondary brain injury, the Brain Trauma Foundation (BTF) guidelines from 2007 advocate intracranial pressure (ICP) monitoring and maintaining an ICP below a threshold of 20-25 mmHg (Brain Trauma Foundation et al., 2007) . This is based upon evidence demonstrating worse outcomes in patients with intracranial hypertension above this threshold (Brain Trauma Foundation et al., 2007; Romner and Grande, 2013; Zeng et al., 2014) .
In addition to monitoring ICP, many centers monitor partial brain oxygen tension (P bt O 2 ), a marker of the oxygen available in the brain for adenosine triphosphate production, which also reflects the balance between oxygen delivery and consumption (De Georgia, 2014) . Both raised ICP and low P bt O 2 have been shown to be independent predictors of poor prognosis in severe TBI, and BTF guidelines advocate initiating therapy to increase P bt O 2 if it falls below 15 mmHg ( Jaeger et al., 2006; Jaeger et al., 2007; Chang et al., 2009; Jaeger et al., 2010; Oddo et al., 2011) . However, contemporary articles suggest that a threshold of 20 mmHg may be more beneficial (Longhi et al., 2007; Chang et al., 2009; Oddo et al., 2011; Le Roux et al., 2014; Oddo and Bosel, 2014) .
Therapeutic hypothermia (TH), the controlled lowering of core body temperature below 36°C, is currently used as a treatment modality for neonatal hypoxic ischemic encephalopathy and postcardiac arrest (Arrich et al., 2009; NICE, 2011) . There is also emerging evidence that it may be beneficial in the management of ischemic stroke (van der Worp et al., 2010) .
Despite conflicting evidence, TH is often used in intensive care units (ICUs) to manage patients following severe TBI (Sydenham et al., 2009; Hutchinson et al., 2013; Crossley et al., 2014) . Neither the 2007 BTF guidelines nor a Cochrane review from 2009 support the use of TH in the management of severe TBI (Brain Trauma Foundation et al., 2007; Sydenham et al., 2009 ). However, a recent systematic review by Crossley et al. (2014) found some evidence to suggest that TH may be of benefit in the management of TBI. Both the Cochrane review and the review by Crossley et al. (2014) note that the evidence to support TH comes from low-quality trials, which have a tendency to overestimate the treatment effect, and state the need for more high-quality trials.
The Eurotherm3235 trial is a pragmatic multicenter randomized controlled trial investigating the effects of TH (32-35°C) on the outcome after TBI. TH is titrated to reduce ICP in patients following TBI who have an ICP >20 mmHg refractory to stage one treatment ( Fig. 1) (Andrews et al., 2011; Andrews, 2012) . Participants are randomized to either a control or intervention group and receive standard care without TH or standard care with TH, respectively as per the Eurotherm3235 trial protocol (Andrews et al., 2011) .
This study reports the retrospective analysis of prospectively collected data from the first 17 patients enrolled on the Eurotherm3235 trial in Edinburgh who were monitored using the Licox system. We examined the effect of induction of TH on ICP and P bt O 2 .
Materials and Methods

Ethical approval and consent
Ethical approval for the Eurotherm3235 trial was granted by the Scotland A Research Ethics Committee. Full consent was obtained from/for all patients, copies of which are retained within the patient's hospital notes and the Welcome Trust Clinical Research Facility, Edinburgh. The trial has been conducted in accordance with Good Clinical Practice guidelines.
Study design and patient selection
The study was a retrospective analysis of prospectively collected data from the first 17 patients enrolled into the Eurotherm3235 trial at the Western General Hospital, Edinburgh. This is a subgroup analysis of patients who received Licox monitoring from a single center, hence the small study number. Analysis of the Eurotherm3235 trial is ongoing but does not include multicenter analysis of P bt O 2 .
Patients were randomized to standard treatment based on the 2007 BTF guidelines or standard treatment and TH by an online randomization service (www.eurotherm3235trial.eu) as soon as possible after meeting the inclusion/exclusion criteria. Inclusion criteria lead to recruitment of patients less than 72 hours after TBI with a primary closed brain injury and an ICP >20 mmHg refractory to stage one treatment without obvious reversible causes and with an abnormal computed tomography (CT) head scan ( Fig. 1 ). We excluded hypothermic patients (<36°C), those already receiving cooling therapy, those receiving barbiturates before randomization, and patients unlikely to survive the next 24 hours in the opinion of the admitting neurosurgeon.
Patients were managed according to the 2007 BTF guidelines, intubated and ventilated to achieve a PaCO 2 of 4.5-5.0 kPa (at 37°C), sedated and nursed with 30°head elevation. Cerebral perfusion pressure was maintained at q60 mmHg by manipulating mean arterial pressure with fluids and noradrenaline and limiting ICPp20 mmHg. Hypothermia was initiated in the intervention group with 20-30 mL/kg of refrigerated 0.9% saline given intravenously and maintained with cooling blankets to an initial target temperature of 35°C. If ICP was not maintained below 20 mmHg, the depth of cooling was increased in 0.5°C increments to a maximum depth of 32°C. TH was maintained for a minimum of 48 hours and continued until ICP was no longer dependent upon hypothermia.
Refractory intracranial hypertension in either group lead to an escalation of therapy, including the use of 125 mL of 5% sodium chloride or 200 mL of 20% mannitol (approximately equimolar) as a bolus injection. Paralysis, further CT imaging and surgical intervention were also available.
Pyrexia in the control group (>38°C) was managed with paracetamol and cooling to normothermia (36.5-37.5°C). All patients received seizure prophylaxis with a loading dose of Phenytoin (20 mg/kg) and a maintenance dose (4-5 mg/kg) for 7 days postinjury. A comprehensive protocol was used to prevent and treat shivering in the cooled patients. Regular paracetamol was administered to patients and their peripheries were wrapped. Countercurrent surface warming and clonidine were both available according to the protocol and persistent shivering was not common in the Edinburgh center.
A Licox monitor (Integra, Lyon, France) recorded ICP, P bt O 2 , and brain temperature through fiber optic pressure catheter, oxygen electrode, and thermistor, respectively. The Licox Ò probe was inserted into the brain parenchyma through a dedicated triple-lumen bolt which was placed by a burr hole. The bolt was placed so that the monitors were inserted into the frontal white matter, in the nondominant hemisphere for diffuse injuries or on the side of maximal injury in focal injuries. The probe was not placed in nonviable tissue. Core body temperature was measured by rectal thermometer. The ICU Pilot software (CMA, Stockholm, Sweden) integrated data from the monitors to a bedside computer each minute until ICP monitoring was considered no longer required. See Figure 2 for study flow chart.
Data and statistical analysis
The first 2 hours of P bt O 2 data recorded were not included in the analysis to reduce artifact from the Licox monitor (Geukens and Oddo, 2012; De Georgia, 2014) . Data from 17 patients, 9 intervention and 8 controls, were analyzed at four time points: Time 0, the hour before randomization (induction of cooling or control); Time 1, the first hour of hypothermia (<35°C); Time 2, the first episode of stable hypothermia (<35°C), defined as 2 consecutive hours of hypothermia; and Time 3, 6 hours of stable hypothermia. Values are given as the meanstandard error of the mean unless otherwise stated. One-way repeated measures of variance (analysis of variance [ANOVA]) were performed to identify differences within each group and paired Student's t-tests were performed to identify differences within the groups at the set time points. Independent Student's t-tests were performed to identify differences between the groups. All statistical tests were performed using Statistical Package for Social Sciences 20.0 (SPSS version 20; IBM, Inc., Armonk, NY).
Results
Control group demographics
The mean age of the participants was 34 years. All eight participants were male. Three patients suffered extradural hemorrhages (EDHs) as their primary injury, two subdural hem-orrhages (SDHs), two traumatic subarachnoid hemorrhages, and one patient suffered a diffuse injury. Three participants had nondepressed skull fractures. The median Glasgow coma score (GCS) on admission to the emergency department was 7 (range 3-14, see Table 1 ).
Intervention group demographics
The mean age of the participants was 41 years. Two participants were female, seven were male. Three patients suffered EDH as their primary injury, three had diffuse injuries, one had contusions, and one had diffuse injuries and a SDH. Five patients had nondepressed skull fractures and one patient had a depressed skull fracture. The median GCS on admission to the emergency department was 7 (range 3-14, see Table 1 ).
Time to target temperature, hemoglobin, FiO 2 , PaO 2 , and PaCO 2
The mean time to target temperature (<35°C) in the intervention group was 7 hours (421 -72 minutes) after randomization, due to long lead times to initiation of TH following prerandomization hypertonic therapy. There was no significant change in FiO 2 from precooling to target temperature in the intervention group (median 0.35 [0.30-0.55] vs. 0.30 [range 0.30-0.55] p > 0.05) and there was no significant difference in FiO 2 between the two groups. PaO 2 and PaCO 2 values were not significantly different from precooling to target temperature: Precooling PaO 2 16.1 -0.9, target temperature 16.3 -1.6 kPa, p > 0.05; precooling PaCO 2 4.5 -0.1, target temperature 4.5 -0.2 kPa, p > 0.05. There was no statistically significant difference in PaO 2 or PaCO 2 values between the two groups. Hemoglobin values were not significantly different between intervention and control groups and were not different at precooling to target temperature in the intervention group (10.1 -0.4 vs. 9.7 -0.4, p > 0.05).
There was no significant difference in the number of osmotic agents used between the control and intervention groups (1, range 0-4 and 0-5, respectively, p > 0.05).
Intracranial pressure
In the intervention group, the ICP decreased by a mean of 4.3 -1.6 mmHg ( p < 0.04) from 15.7 to 11.4 mmHg from Time 0 to Time 1 (Figs. 3 and 4 ). This decrease in ICP was maintained from Time 0 to Times 2 and 3. A one-way repeated measures ANOVA in the intervention group was consistent with these results: F(3, 24) = 6.13, p < 0.01. There was no statistically significant difference in ICP in the control group between these times. A two-way repeated measures ANOVA reveals a difference between the two groups at these time points: F(3,45) = 4, p < 0.02.
Partial brain oxygen tension
Paired t-tests demonstrated a statistically significant difference between Time 0 and Time 2, where there was a mean decrease in P bt O 2 of 7.8 -3.1 mmHg ( p < 0.05) from 30.2 to 22.4 mmHg (Fig. 5) . A one-way repeated measures ANOVA for the intervention group also showed a difference in P bt O 2 with time F(3,18) 4.60, p < 0.02. Three patients in the intervention group had a decrease in P bt O 2 from >25 mmHg at Time 0 to <20 mmHg at Time 3.
There was no statistically significant difference between Time 0 and any other times in the control group. However, paired t-tests demonstrated a mean decrease of 3.47 -1.02 mmHg ( p < 0.02) between Time 1 and Time 3, and a mean decrease of 3.48 -1.27 mmHg ( p < 0.03) between Time 2 and Time 3 in the control group (Fig. 6 ). There was no statistically significant difference between the two groups in terms of the change in P bt O 2 (Fig. 7) .
Discussion
Intracranial pressure
Starting ICP in this report was less than 20 mmHg (ET3235Trial protocol) because a single hypertonic treatment was given pending randomization which also resulted in long lead times to initiation of cooling. TH reduced ICP by a mean of 4.3 -1.6 mmHg from precooling to the first episode of stable hypothermia (*27%), despite pretreatment with hypertonic therapy. The reduction in ICP was maintained at 6 hours and there was no further decrease with prolonged hypothermia, which is consistent with previous studies (Shiozaki et al., 1993; Schwab et al., 1998) . This is a comparable reduction to mannitol and hypertonic saline, which are reported to reduce ICP by 10-51% and have similar efficacy ( James et al., 1977; James, 1980; Freshman et al., 1993; Berger et al., 1995; Qureshi et al., 1998 Qureshi et al., , 1999a Qureshi et al., , 1999b Sorani et al., 2008) .
Neither of these therapies is without risk. Reported adverse effects of mannitol include renal failure, electrolyte abnormalities, acidosis, hypotension, and congestive heart failure. Reported adverse effects of hypertonic saline include renal failure and electrolyte abnormalities in addition to other theoretical concerns (Torre-Healy et al., 2012) . Furthermore, hyperosmolar therapy is limited in that mannitol leads to a short-lived reduction in ICP with diminishing returns and the prolonged use of hypertonic saline over 72 hours has been shown to increase mortality ( James et al., 1977; McGraw, 1978) . Therefore, TH may be beneficial in providing a persistent reduction of ICP. It is not suggested that TH is used as an alternative to hyperosmolar therapies, but rather that it may help to reduce the number of therapies required when used in combination.
TH however, is not a risk-free intervention either, and can be associated with a number of adverse effects, including arrhythmias, electrolyte disturbances, and pneumonia. While pneumonia is often reported following TH, a Cochrane review from 2009 found that the trend toward an increased risk of pneumonia was not significant and the quality of evidence supporting it was poor (Sydenham et al., 2009) .
This study supports others in finding that TH reduces ICP, but it does not suggest that outcomes are improved or that the use of hyperosmolar agents is reduced (Table 2) . We await the full analysis of the Eurotherm3235 trial that will conclusively demonstrate whether TH improves outcomes or not.
Partial brain oxygen tension
Both groups in this report demonstrated a decrease in P bt O 2 with time. In the intervention group there was a significant decrease of 7.8 -3.1 mmHg from 30.2 to 22.4 mmHg. In the control group, no statistically significant decrease was seen from Time 0 to any other time points. However, it is worth noting that half of the control group were not included in the Time 0 analysis due to missing data (n = 4/8). The first 2 hours of data from randomization were not included in the analysis because it coincided with the time we allowed for the oxygen electrode to stabilize. In the remaining patients, P bt O 2 recording was already in place before randomization and the data were able to be included.
There was a statistically significant decrease in P bt O 2 in the control group between Time 1 and 3 and Time 2 and 3 of 3.47 -1.02 and 3.48 -1.27 mmHg, respectively. It could be that a statistically significant difference between Time 0 and the other time periods would have been seen if all data were present at Time 0. There was no statistically significant difference between the two groups.
Previous studies have investigated the effect of hypothermia on P bt O 2 with conflicting results. Gupta et al. (2002) saw a decrease in P bt O 2 in a study of 30 patients cooled to FIG. 6. Boxplot of partial brain oxygen tension versus time in the control group. Time 0, prerandomization; Time 1, first hour of hypothermia (<35°C); Time 2, first episode of stable hypothermia (<35°C); Time 3, 6 hours of hypothermia (<35°C). There was no statistically significant difference between Time 0 and the other time points.
FIG. 7. Changes in partial brain oxygen tension with time: intervention, and control groups. Time 0, prerandomization; Time 1, first hour of hypothermia (<35°C); Time 2, first episode of stable hypothermia (<35°C); Time 3, 6 hours of hypothermia (<35°C). There was no statistically significant difference between the two groups in terms of the change in P bt O 2 . a minimum of 33°C and concluded that decreasing brain temperature below 35°C may impair brain tissue oxygenation. However, it has been argued that the Paratrend 7 (Diametrics Medical, High Wycombe, United Kingdom) sensor used to measure P bt O 2 in this study was not corrected for temperature and so did not reflect an accurate P bt O 2 . In contrast, Zhang et al. (2002) found that mild hypothermia (31.5-34.9°C) increased the mean (SD) P bt O 2 from 9.6 (6.8) to 28.7 (8.8) mmHg in 18 patients with severe TBI. Patients in this study received TH within 20 hours following TBI and had P bt O 2 recorded within the first 24 hours. Given the very low initial P bt O 2 and subsequent increase within 24 hours following injury, it has been suggested that this increase was attributable to early changes in cerebral blood flow (CBF) rather than an effect of hypothermia (Andrews and Gupta, 2003) .
Decreases in P bt O 2 have been associated with poor outcomes independent of raised ICP and the combination of both a raised ICP and decreased P bt O 2 appears worse than intracranial hypertension in isolation (Chang, 2009) . Normal levels of P bt O 2 in neurosurgical patients are reported as between 23 and 35 mmHg, with lower values coming from probes sited deeper in brain tissue (Hoffman et al., 1996; Dings et al., 1998; Pennings et al., 2008) . While the decrease of P bt O 2 in the intervention group is significant, the mean value did not decrease below the threshold of 15 mmHg recommended for intervention by the 2007 BTF guidelines (Brain Trauma Foundation et al., 2007) , nor did it decrease below 20 mmHg, the suggested threshold for compromised brain oxygen/moderate brain hypoxia (Le Roux et al., 2014) . However, when looking at the individual value plots (Fig. 8) for the intervention group, one can see that three participants demonstrated a change in P bt O 2 from above 25 mmHg before cooling to less than 20 mmHg after 6 hours of target temperature. It is unclear why certain patients exhibit this decrease in P bt O 2 while others do not, but further investigation is warranted to identify those patients likely to benefit most from targeted temperature management.
Arterial blood gases were analyzed using the alpha stat method to maintain autoregulation, which was consistent with current practice in the units that participated in the trial. This approach has been undertaken in other contemporary hypothermia trials, such as NABISH II and TTM (Clifton et al., 2011; Nielsen et al., 2013) . Despite this, there was no significant difference in our precooling and target temperature PaCO 2 and PaO 2 values, which is important given the dependence of P bt O 2 upon systemic oxygenation and transport (Rosenthal et al., 2008) . If the decrease in P bt O 2 was due to changes in PaCO 2 and PaO 2 with temperature (Gay-Lussac's Law), we would expect to see changes in PaO 2 and PaCO 2 . Therefore, the decrease in P bt O 2 may be due to reduced CBF. Anemia has been associated with a decrease in P bt O 2 following TBI . The current study found no difference in hemoglobin levels between either the two groups, or in the intervention group at precooling or target temperature to account for the change in P bt O 2 . The hemoglobin of two patients in the control group and three patients in the intervention group was < 9 g/dL, the level at which P bt O 2 is thought to be compromised . However, in those randomized to the intervention group, the decreased hemoglobin was present before the patients reached target temperature.
Balancing oxygen delivery with demand Tokutomi et al. (2003) have previously studied the optimal temperature to reduce ICP while resulting in minimal unfavorable outcomes in patients with TBI and concluded that this temperature is about 35°C. In their study from 2002, decreases in ICP were most noticeable between 35°C and 36°C and the incidence of jugular venous bulb oxygen desaturation was also decreased at these temperatures. However, oxygen consumption, measured through indirect calorimetry, and oxygen delivery also progressively decreased. Below 35°C Tokutomi et al. (2003) found that oxygen delivery decreased more than the decrease in oxygen demand resulting in an overall deficit.
A potential explanation for the decrease in ICP with hypothermia is a decrease in CBF (PaCO 2 related), which could also explain the decrease in oxygen delivery (Marion et al., 1993; Shiozaki et al., 1993) . Hypothermia is thought to decrease cerebral metabolic rate for oxygen (CMRO 2 ) and there may be an associated decrease in oxygen demand (Keller, 2000) . While we believe we can reduce ICP and CMRO 2 , perhaps we are yet to find the balance between decreasing CBF/ICP and maintaining adequate oxygen delivery and are causing unwanted decreases in P bt O 2 because of this.
Limitations of the study
The present study has some limitations that need to be considered. Due to the nature of the patient population and TH, it is not possible to blind researchers from the administration of TH. In addition, the researchers were not blinded for the analysis of the two groups which could potentially lead to a bias of analysis.
Although we have attempted to correct the time taken to reach hypothermia by comparing prerandomization values with the different time periods, we must acknowledge that the mean time to target temperature was *7 hours. Given that early initiation of TH is considered beneficial in improving efficacy, it could be that a greater decrease in both ICP and P bt O 2 would have been seen in the intervention group if the time to reach target temperature was reduced.
Finally, it should be noted that there were missing data. For example, data were not recorded due to a faulty connection attached to the P bt O 2 monitor or a connection accidentally detached. Some of the data were missing in a nonrandom manner. An example is missing ICP and P bt O 2 data when patients were transferred to the CT scanner because monitors were detached to facilitate patient transfer. Due to the small sample size and relatively small amount of data missing, statistical models to analyze the effect of missing data were not performed. The most apparent effect of the missing data is seen when analyzing P bt O 2 at Time 0 in both the control and intervention groups as described above.
Conclusion
TH is an effective addition to the management of intracranial hypertension and could potentially reduce the number of hyperosmolar therapies required. It remains to be seen whether the use of TH, titrated to reduce ICP, will result in improved outcomes in patients following TBI. TH below 35°C could reduce oxygen delivery more than oxygen demand leading to reduced cerebral oxygenation and it is unclear why some patients exhibit a greater decrease in P bt O 2 than others. Further analysis of patients enrolled on the Eurotherm3235 trial is required to assess the effects of TH on P bt O 2 .
